Genscript Biotech (HKG:1548) Has A Pretty Healthy Balance Sheet
Sep 08
Have your own idea? Try our Stock Screener
Hong Kong (HSI) Life Sciences Industry Analysis
UpdatedSep 12, 2025
DataAggregated Company Financials
Companies11
- 7D2.1%
- 3M32.8%
- 1Y96.0%
- YTD93.8%
In the last week, the Life Sciences industry is flat overall, with Medtide standing out by going down 7.6%. As for the the longer term, the industry is up 106% over the past 12 months. As for the next few years, earnings are expected to grow by 30% per annum.
Industry Valuation and Performance
Has the Hong Kong Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 12 Sep 2025 | HK$325.0b | HK$41.9b | HK$6.2b | 45.5x | 52.3x | 7.8x |
| Sun, 10 Aug 2025 | HK$272.0b | HK$37.2b | HK$2.7b | 57.8x | 99.4x | 7.3x |
| Tue, 08 Jul 2025 | HK$223.8b | HK$37.2b | HK$2.7b | 44.7x | 81.6x | 6x |
| Thu, 05 Jun 2025 | HK$208.7b | HK$36.2b | HK$2.6b | 28x | 80.1x | 5.8x |
| Sat, 03 May 2025 | HK$197.0b | HK$35.4b | HK$2.5b | 27.3x | 77.6x | 5.6x |
| Mon, 31 Mar 2025 | HK$224.6b | HK$35.6b | HK$2.6b | 30.6x | 88.1x | 6.3x |
| Wed, 26 Feb 2025 | HK$199.9b | HK$35.8b | -HK$1,057,904,176.47 | 56.3x | -189x | 5.6x |
| Fri, 24 Jan 2025 | HK$153.2b | HK$35.8b | -HK$1,060,836,392.39 | 54.3x | -144.4x | 4.3x |
| Sun, 22 Dec 2024 | HK$156.5b | HK$35.7b | -HK$1,059,187,344.54 | 60.5x | -147.7x | 4.4x |
| Tue, 19 Nov 2024 | HK$135.1b | HK$36.0b | -HK$1,058,297,462.62 | 43x | -127.7x | 3.8x |
| Thu, 17 Oct 2024 | HK$148.7b | HK$35.7b | -HK$659,357,511.11 | 24.3x | -225.5x | 4.2x |
| Sat, 14 Sep 2024 | HK$147.3b | HK$35.9b | -HK$659,882,883.69 | 24.7x | -223.2x | 4.1x |
| Mon, 12 Aug 2024 | HK$100.9b | HK$35.0b | HK$2.5b | 17.5x | 40.6x | 2.9x |
| Wed, 10 Jul 2024 | HK$86.1b | HK$33.4b | HK$3.1b | 18.4x | 28x | 2.6x |
| Fri, 07 Jun 2024 | HK$89.9b | HK$33.5b | HK$3.1b | 24.7x | 29.1x | 2.7x |
| Sun, 05 May 2024 | HK$112.5b | HK$33.5b | HK$3.1b | 32.3x | 36.4x | 3.4x |
| Tue, 02 Apr 2024 | HK$116.9b | HK$33.6b | HK$3.1b | 34.4x | 37.7x | 3.5x |
| Thu, 29 Feb 2024 | HK$138.0b | HK$32.3b | HK$3.0b | 54.5x | 46.4x | 4.3x |
| Sat, 27 Jan 2024 | HK$169.8b | HK$32.5b | HK$3.0b | 69.7x | 56.4x | 5.2x |
| Mon, 25 Dec 2023 | HK$201.0b | HK$32.5b | HK$3.0b | 92.1x | 66.8x | 6.2x |
| Wed, 22 Nov 2023 | HK$295.8b | HK$32.2b | HK$3.0b | 86.8x | 99.3x | 9.2x |
| Fri, 20 Oct 2023 | HK$244.0b | HK$30.1b | HK$2.7b | 44x | 91.6x | 8.1x |
| Sun, 17 Sep 2023 | HK$235.4b | HK$30.2b | HK$2.7b | 41.8x | 87.6x | 7.8x |
| Tue, 15 Aug 2023 | HK$232.5b | HK$28.3b | HK$2.7b | 23.6x | 86.4x | 8.2x |
| Thu, 13 Jul 2023 | HK$202.6b | HK$28.5b | HK$2.7b | 22.1x | 74.2x | 7.1x |
| Sat, 10 Jun 2023 | HK$238.2b | HK$28.7b | HK$2.8b | 20.7x | 85.9x | 8.3x |
| Mon, 08 May 2023 | HK$254.2b | HK$29.5b | HK$2.9b | 22.9x | 87x | 8.6x |
| Wed, 05 Apr 2023 | HK$240.2b | HK$29.6b | HK$3.0b | 16x | 80.3x | 8.1x |
| Fri, 03 Mar 2023 | HK$301.0b | HK$26.3b | HK$2.0b | 25x | 146.9x | 11.4x |
| Sun, 29 Jan 2023 | HK$372.9b | HK$26.6b | HK$2.1b | 28.8x | 175x | 14x |
| Tue, 27 Dec 2022 | HK$284.9b | HK$26.0b | HK$2.0b | 24.9x | 142.6x | 10.9x |
| Thu, 24 Nov 2022 | HK$251.0b | HK$25.6b | HK$1.9b | 24.4x | 133.6x | 9.8x |
| Sat, 22 Oct 2022 | HK$226.6b | HK$25.5b | HK$1.8b | 20.5x | 123.1x | 8.9x |
| Mon, 19 Sep 2022 | HK$271.9b | HK$26.1b | HK$2.0b | 23.2x | 136.6x | 10.4x |
Price to Earnings Ratio
136.6x
Current Industry PE
- Investors are optimistic on the Hong Kong Life Sciences industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 53.6x which is higher than its 3-year average PE of 24.4x.
- The 3-year average PS ratio of 6.6x is lower than the industry's current PS ratio of 8.0x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have grown 46% per year over the last three years.
- Revenues for these companies have grown 17% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare industry?
| HK Market | 3.74% | |
| Healthcare | 2.01% | |
| Life Sciences | 2.06% | |
| Clinical Research and Equipment | 2.06% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 2269 WuXi Biologics (Cayman) | HK$36.00 | 2.0% +HK$3.5b | 208.2% | PE31.9x | |
| 2228 XtalPi Holdings | HK$10.22 | 7.4% +HK$3.0b | -27.2% | PS59.1x | |
| 2268 WuXi XDC Cayman | HK$64.20 | 1.7% +HK$1.3b | 213.9% | PE53.3x | |
| 1521 Frontage Holdings | HK$1.41 | 5.2% +HK$141.9m | 143.1% | PE95.7x | |
| 6118 Austar Lifesciences | HK$1.21 | 6.1% +HK$35.9m | 105.1% | PE16.1x |